header logo image


Page 471«..1020..470471472473..480490..»

Opinion: Is there hope for USA’s international leadership after COVID-19? – Los Angeles Times

July 10th, 2020 6:46 pm

Since December 31, 2019, COVID-19 has been raging throughout the world. Many causes have been attributed to its success in infecting millions of people, such as how it is an airborne-illness or how the disease can last long periods of time in cold weather. However, according toThe National Academies of Science, Engineering and Medicine,one nations leadership can be a huge contributor to the prevention of global pandemics, such as the one that is currently happening.

Undoubtedly, as the United States is the current most powerful country in the world, our nation should have stepped up to the task, but unfortunately, we didnt.

Thus, because the United States did not sufficiently grasp just how devastating this new disease would be, the USs reaction to it was subpar. There needed to be a more coordinated approach on the national level. On the global level, there should have been more allocation of resources amongst different countries, with the US and other wealthy and powerful countries leading the path towards the response to COVID-19.

As the world superpower, the US should not have been greatly impacted by the COVID-19 and the reason it has suffered the worst outbreak in the world is due to the lack of effective responses.

After the terrible spreading of COVID-19 amongst the population in Wuhan, China, there has been a lot of commotion in that country to try to stop this novel infection from spreading rapidly. They erected hospitals in a matter of days and, according to the Deccan Herald and South China Morning Post, had many doctors from all over China rush to aid the coronavirus victims.

After winter break, while the virus was spreading rapidly across Wuhan, I was in school, coming off a nice vacation snowboarding in Canada. Like many of my classmates and teachers, I was not as worried about the coronavirus as I should have been, as the disease was thousands of miles away from me overseas.

With this thought process, many Americans, including the US president, have disregarded the coronavirus disease until the last possible minute, when the US started reporting that there were outbreaks in many major cities.

Back in February, as reported byFactCheck.org, President Trump had said in a speech that there was no need to worry about the coronavirus as the United States has the best doctors in the world and that he has the coronavirus very much under control.

Although this reassurance may have helped boost the morale of US citizens in the short term, the long term effects were that the US was very dismissive about just how severe the coronavirus was. Even with travel bans in place, many US citizens started being diagnosed with coronavirus, eventually leading to lockdowns in many school districts and companies, possibly costing the US more than 2 trillion dollars, according to theNew York Times.

Thus, due to the incorrect mindset and late actions of the US government, the United States reaction to the coronavirus was very unsatisfactory, to say the least.

Speaking of unsatisfactory, on the national level, the US could have dealt with the spread of the coronavirus in a much more efficient way by implementing more extreme measures.

According to Vox, after learning from their mistakes during the MERS outbreak in 2015, South Korea passed an urgent law, effective only in pandemics, to start tracking individuals with the coronavirus, providing updates to their latest locations in order to prevent other civilians from crossing paths with the infected individuals. Although, to us Americans, this seems like a blatant intrusion of privacy, they only allow it in the case of a public health emergency. South Korea has been able to successfully contain the coronavirus to only a small percent of its population and has leveled off the curve and rate of infection.

On the other hand, America is struggling to prevent the coronavirus from spreading, with over three million cases, as of July 10, according to the CDC. With the current technology and the money available at our disposal, the US should have implemented the measures that South Korea utilized: tracking the individuals who were infected.

Although many would argue against this severe approach, this would be the best method in preventing people from contacting others with the coronavirus as proven by the fact that South Korea is able to manage and control their outbreaks much better than the U.S., even after, as reported in The Diplomat, several outbreaks.

In addition, in Century of Outbreaks, the authors quote Amanda McClelland, senior vice president of Prevent Epidemics at Resolve to Save Lives, that countries tend to fall into a cycle of panic and neglect of pandemics, noting that once a horrible global pandemic has passed, many countries stop worrying and funding for the future pandemic preventative measures.

With the 2009 influenza pandemic as the latest epidemic to hit the US, the US should have started preparing since then, but unfortunately, as the effects of the coronavirus display, we have not. I point this out, even though we cannot go back in time to fix this mistake, because the US should have focused more on planning for future pandemics and not thinking that in time, everything will sort itself out.

Although sometimes pandemics seem too far into the future, time is of the essence and there needs to be adequate planning, which the US did not have in fighting the coronavirus, but other countries, like South Korea, did. Therefore, there need to be more rigorous approaches in stopping COVID-19 today, as well as planning for the future.

On the global scale, coronavirus can be better treated with the US being the leader and working with other countries to prevent later outbreaks of the coronavirus or any future pandemic.

According to Century of Outbreaks, a huge factor in pandemic prevention is the collaboration of many countries, whether that be pooling resources such as funding or vaccine development or helping surveillance of the coronavirus. As of now, many countries are dealing with outbreaks independently and not as a global effort, especially with the US struggling to contain the coronavirus from spreading within its own borders.

If the world wants to quell this COVID-19 pandemic, the US needs to step up alongside other developed countries to share resources and serve as role models to the world.

Adding on, Century of Outbreaks also mentions that developing countries, due to how severely pandemics impact their populations, can gather more data on outbreaks, and in doing so, contribute this vital information to the development of treatments and vaccines for the world community.

However, many developing countries usually get cheated despite their contributions due to other developed countries that have already bought most of the vaccines or health products needed to treat pandemics, leaving none for the developing countries.

In the case of COVID-19, the US should enlist the help of these developing countries for their intel or research on this disease to better fight this pandemic. In turn, the US should sign contracts to ensure that these developing countries will be provided with assistance against future pandemics. Not only will we better contain the outbreaks that will affect us, but we will also build stronger international friendships and alliances.

Although the US may be the most powerful country in the world, it is still beset with flaws, especially in the face of disastrous pandemics, as COVID-19 has revealed. The USs response towards the coronavirus was disastrous.

Finally, on a global scale, the US should have been the leader in addressing the coronavirus and a role model to other countries as well.As it is our responsibility as a global leader, we can do better and we should do better, not just for ourselves, but for everyone.

See original here:
Opinion: Is there hope for USA's international leadership after COVID-19? - Los Angeles Times

Read More...

Research Report and Overview on Canine Arthritis Treatment Market, 2019-2026 – Cole of Duty

July 10th, 2020 6:44 pm

The Canine Arthritis Treatment Market research report added by Market Study Report, LLC, provides a succinct analysis on the recent market trends. In addition, the report offers a thorough abstract on the statistics, market estimates and revenue forecasts, which further highlights its position in the industry, in tandem with the growth strategies adopted by leading industry players.

The Canine Arthritis Treatment market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Canine Arthritis Treatment market and the trends that will prevail in this industry.

Request Sample Report @https://www.mrrse.com/sample/17398?source=atm

What pointers are covered in the Canine Arthritis Treatment market research study?

The Canine Arthritis Treatment market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Canine Arthritis Treatment market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Canine Arthritis Treatment market report Elucidated with regards to the competitive landscape of the industry:

The second dominant market in canine arthritis treatment is Germany owing to the rise in prevalence of chronic diseases in animals, particularly dogs. It has been found that with growing age of pets, the prevalence of diseases such as allergies, lower appetite, reduced energy, arthritis, lameness, dysplasia and behavioural anxieties increases, especially in dogs and cats. This growth in terms of pet adoption in European countries and increasing number of pets suffering from arthritis is likely to boost the growth of canine arthritis treatment in Europe. This has been driving the demand for innovative therapies and drugs in Canine Arthritis Treatment, such as stem cell Canine Arthritis Treatment and arthritis drugs NSAIDs and opioids. Canine arthritis treatment/drugs in Germany have taken initiatives to incentivize innovation in the field of veterinary treatment in order to address the urgent need of better veterinary care and to combat rapid growing prevalence of animal diseases. Additionally, increasing expenditure on vet care in high economic European countries such as Germany, France and the U.K. also boosts the growth of the market for canine arthritis treatment. As per the American Pet Products Association, about US$ 6.1 Bn was spent on vet care in 2017 in Europe.

Increasing pet adoption in China and India is expected to drive the growth of the canine arthritis treatment market in Asia-Pacific. In Japan and the Middle East and Africa, the population of dogs is decreasing due to poor vet care facilities, which is expected to hamper the growth of canine arthritis treatment market to some extent.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/17398?source=atm

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Canine Arthritis Treatment market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Canine Arthritis Treatment market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Canine Arthritis Treatment market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

Buy This Report @ https://www.mrrse.com/checkout/17398?source=atm

Some of the Major Highlights of TOC covers:

See original here:
Research Report and Overview on Canine Arthritis Treatment Market, 2019-2026 - Cole of Duty

Read More...

Connective Tissue Growth Factor Market : Industry Trends and Developments 20192025 – Cole of Duty

July 10th, 2020 5:50 pm

Global Connective Tissue Growth Factor Market Report 2019 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Connective Tissue Growth Factor industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2714067&source=atm

For competitor segment, the report includes global key players of Connective Tissue Growth Factor as well as some small players.

Segment by Type, the Connective Tissue Growth Factor market is segmented intoBLR-200IB-DMDOLX-201PBI-4050Others

Segment by Application, the Connective Tissue Growth Factor market is segmented intoHypertrophic ScarsOpthalmologyGenetic DisordersLiver FibrosisOthers

Regional and Country-level AnalysisThe Connective Tissue Growth Factor market is analysed and market size information is provided by regions (countries).The key regions covered in the Connective Tissue Growth Factor market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.Competitive Landscape and Connective Tissue Growth Factor Market Share AnalysisConnective Tissue Growth Factor market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Connective Tissue Growth Factor business, the date to enter into the Connective Tissue Growth Factor market, Connective Tissue Growth Factor product introduction, recent developments, etc.

The major vendors covered:BLR Bio LLCFibroGen IncProMetic Life Sciences IncRXi Pharmaceuticals Corp

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2714067&licType=S&source=atm

Important Key questions answered in Connective Tissue Growth Factor market report:

What will the market growth rate, Overview, and Analysis by Type of Connective Tissue Growth Factor in 2024?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Connective Tissue Growth Factor market?

What is Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles?

Who Are Opportunities, Risk and Driving Force of Connective Tissue Growth Factor market? Knows Upstream Raw Materials Sourcing and Downstream Buyers.

Who are the key manufacturers in space? Business Overview by Type, Applications, Gross Margin, and Market Share

What are the opportunities and threats faced by manufacturers in the global market?

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2714067&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Connective Tissue Growth Factor product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Connective Tissue Growth Factor , with price, sales, revenue and global market share of Connective Tissue Growth Factor in 2019 and 2015.

Chapter 3, the Connective Tissue Growth Factor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Connective Tissue Growth Factor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2019 to 2025.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2019 to 2025.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2019 to 2025.

Chapter 12, Connective Tissue Growth Factor market forecast, by regions, type and application, with sales and revenue, from 2019 to 2025.

Chapter 13, 14 and 15, to describe Connective Tissue Growth Factor sales channel, distributors, customers, research findings and conclusion, appendix and data source.

More:
Connective Tissue Growth Factor Market : Industry Trends and Developments 20192025 - Cole of Duty

Read More...

COVID-19 Impact and Recovery Solutions on Non-invasive Ventilation Devices Market- Business Growth Strategies by Key Players: ResMed, Teijin Pharma,…

July 10th, 2020 5:47 pm

Covid-19 Impact on Global Non-invasive Ventilation Devices Market size, status, overview and forecast 2020-2026

A new report on Non-invasive Ventilation Devices Market has been published by Acquire Market Research. The report provides a thorough analysis of the industry trends, market opportunities, growth drivers essential for market leaders like ResMed, Teijin Pharma, DeVilbiss Healthcare, Philips Respironics, BMC Medical, Fisher & Paykel Healthcare, etc. to capture each and every opportunity that presents itself. The report prepared based on detailed analysis and thorough research examines statistical data points and presents information on market values, potential consumers and the future scope of the market.

In order to identify the growth factors, shortcomings, threats, and the lucrative opportunities that the market will offer in the near future analysis methods such as S.T.E.E.P.L.E., S.W.O.T., Regression analysis, etc. have been utilized to study the underlying factors of the market. While the underlying aspects are studied test models are utilized to study the impact of the underlying factors on the development and trends of the market.

Avail PDF Copy of Latest Research on Non-invasive Ventilation Devices Market @ https://www.acquiremarketresearch.com/sample-request/378316/

Our expert team is consistently working on updated data and information of key players related business processes which values the market. For future strategies and predictions, we provide special section regarding covid-19 situation.

The report also provides a granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. Following are some of the segmentations provided in the report ;

Leading players operating in the global Non-invasive Ventilation Devices market are: ResMed, Teijin Pharma, DeVilbiss Healthcare, Philips Respironics, BMC Medical, Fisher & Paykel Healthcare, Beyond Medical, Covidien (Medtronic), Fosun Pharma, Apex Medical, Kare Medical, Somnetics, 3B Medical, Jiangsu Yuyue medical, Koike Medical, HuNan Beyond Medical

Non-invasive Ventilation Devices Market Growth by Types: CPAP Devices, APAP Devices, BPAP Devices

Non-invasive Ventilation Devices Market Extension by Applications: Homecare, Hospital

The Global version of this report with a geographical classification would cover regions:

North America (USA, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Grab Your Report at an Impressive Discount! With Corporate Email ID @ https://www.acquiremarketresearch.com/discount-request/378316/

In order to simply the value of the report to the readers, the target audiences of the report and various aspects have been listed that would justify the authenticity and uniqueness of the report.

Target Audiences of This Report:

Analysts and Strategic Business Planners

Non-invasive Ventilation Devices Manufacturers, Suppliers and Distributors

Government Regulatory and Research Organizations

Venture Capitalists and Private Equity Firms

Investment Research Firms / Associations

End-Use Industries

Other Key Aspects of Global Non-invasive Ventilation Devices Market Report;

Identification of factors that could alter the current and forecasted growth of the market.

The incorporation of target audience during analytical assessment, to determine the impact of key drivers, restraints, and opportunities in detail.

Utilization of ANOVA test and FRAP method to determine the effect of, alteration in strategies by leading players, political occurrence, change in policies, etc. on current trends and future estimations to depict the imminent investment pockets.

To understand the lucrative trends and to gain a stronger foothold in the industry, the overall Non-invasive Ventilation Devices market potential is determined.

To utilize and capture each opportunity Porters five forces analysis is utilized, to illustrate the potency of the buyers and suppliers in the market.

Have Any Query about covid-19 impact on Non-invasive Ventilation Devices market Ask Our Expert (Use Corporate email ID to Get Higher Priority) @ https://www.acquiremarketresearch.com/enquire-before/378316/

About us:

At Acquire Market Research the database of the company is updated on a daily basis to provide the clients with reports containing the latest trends and in-depth analysis of the industry. While each report initially generated is prepared with a set benchmark of the industry, the reports are customizable to meet the requirements of the client. After careful validation of the report by our expert analysts, the report on Non-invasive Ventilation Devices Market has been published.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

Follow this link:
COVID-19 Impact and Recovery Solutions on Non-invasive Ventilation Devices Market- Business Growth Strategies by Key Players: ResMed, Teijin Pharma,...

Read More...

No ethics when it comes to US enemies, even in the middle of a deadly pandemic – IOL

July 10th, 2020 5:45 pm

By Shannon Ebrahim 16h ago

Share this article:

After a week, she is having trouble breathing, but when she goes to the nearest hospital, there is a shortage of medical staff to process her admission as many have succumbed to the virus due to a lack of PPE (personal protective equipment). There are also no ventilators to assist her to breathe.

She knows this could spell the end of her life, and there will be no one to take care of the three children she has left alone at home.

This is what happens when the noose of sanctions are tightened on a country in the middle of a global health pandemic - a country that already had a collapsing economy thanks to unilaterally imposed US sanctions.

There are no ethics or conscience when it comes to US enemies, even in the middle of a deadly pandemic. If denying Venezuelans life-saving medicine and equipment might hasten the collapse of the Maduro regime, then the US is all for it.

US allies are too scared to fill the vacuum and deliver the desperately needed aid and assistance to Venezuela, even on a humanitarian basis, due to the threat of secondary sanctions on countries that buck the US economic blockade. It is only countries like China, Russia, and Cuba that have assisted the people of Venezuela in their fight against Covid-19.

Foreign Minister Jorge Arreaza was correct when he said in March that the US illegal and unilateral coercive measures against his country were a form of collective punishment.

Under the 1949 Geneva Convention, collective punishment is a war crime and a crime against humanity as defined by the UN International Law Commission. When countries refuse to send medicine and supplies to Venezuela in the middle of a global health pandemic due to the unilateral US sanctions regime, they too are complicit in a war crime.

The US has laid down the gauntlet - any firm that trades with Venezuelas public sector could face secondary sanctions.

But the health infrastructure in Venezuela is run by the state, which has made it virtually impossible to access medical equipment, supplies, Covid-19 testing kits and medicine.

Since the outbreak of the pandemic, airlines and shipping companies have been too afraid to go to Venezuela to deliver essential goods exported from countries that refuse to be cowed by US bully tactics.

As a result, Venezuelans are dying, and the US is under the misguided notion that this will put an end to the great Bolivarian revolution, and finally succeed in its regime change agenda - with a little help from Covid-19.

What is that notorious concept: Dont waste a good crisis?

This inhumanity has not escaped condemnation by senior UN officials. The UN High Commissioner for Human Rights, Michelle Bachelet, has called for sanctions to be eased or suspended during the pandemic.

Three UN Special Rapporteurs have called on the US to lift sanctions on Venezuela due to the severe impact on the human rights of its people.

We have to give it to the Americans: they dont even try to hide or nuance their intentions any more - they put them out there for us on a silver platter. In February, US Secretary of State Mike Pompeo told the Munich Conference that the US seeks to oust Maduro.

In March, at the onset of the coronavirus pandemic, the US tightened its sanctions on the country.

US President Donald Trump wasted no time in waving a red flag to a bull by stationing a naval detachment off the coast of Venezuela, to prove that the US is a very real and present danger.

In May, one of the highest- ranking members of the Republican party, Lindsay Graham, penned an article in the Wall Street Journal which said: The US must be willing to intervene in Venezuela the way it did in Grenada.

In 1983, the US had overthrown the legitimate government of Grenada through military intervention.

Graham went even further to say: If measures are not taken then, the US should move military assets to the region.

But such threats form only part of the range of techniques the US uses to undermine foreign governments it does not find palatable to its national interests. Its what is called a hybrid war.

Another favourite tactic is to pressure the International Monetary Fund to deny such governments much needed funds in the context of a suffocating sanctions regime. The US Treasury Department has pressured the IMF to deny Venezuela access to emergency funds to fight the Covid-19 pandemic.

When President Nicolas Maduro wrote to the IMF requesting a $5 billion loan from the Covid-19 emergency fund to strengthen Venezuelas detection and response systems, the request was flatly denied.

Whoever believed the mantra of the Western-controlled international financial institutions, We are all in this together?

What they should have said is, All lives matter as long as you are not Venezuelan, Cuban, Iranian, or North Korean.

* Shannon Ebrahim is the foreign editor of the Independent Media Group.

Read the original post:
No ethics when it comes to US enemies, even in the middle of a deadly pandemic - IOL

Read More...

13 promising Covid-19 treatments emerging from Israel – The Yucatan Times

July 10th, 2020 4:49 pm

In parallel to vaccine research, theres an urgent need for effective treatments for the respiratory disease caused by the SARS-CoV-2 coronavirus.

ISRAEL (Scientists across the globe are working on vaccines to prevent Covid-19 infection. After initial vaccines are approved, there is an urgent need for effective treatments for the respiratory disease caused by the SARS-CoV-2 coronavirus.

Most potential treatments target the life-threatening lung inflammation typical of covid-19 severe cases. Its caused by a phenomenon called a cytokine storm.

Cytokines are proteins that trigger inflammation as a natural response to infection. In response to a virus overload, in this case, in the lungs, the immune system activates a storm of cytokines. Too many cytokines lead to too much inflammation, which can damage the lungs and cause respiratory distress.

Israeli hospitals were among the first anywhere to use dexamethasone, a steroid drug, to stop cytokines storms and reduce lung inflammation in severely ill Covid-19 patients. However, steroids can suppress the immune response too actively.

Additionally, an Israeli hospital is among the first to do a randomized, double-blind, placebo-controlled clinical trial of ivermectin, a drug to treat parasitic infections in people and animals, to see if it can shorten the duration of the disease if given to Covid-19 patients immediately after diagnosis.

Israelis are also formulating novel therapeutics of their own. Here are 13 potential Israeli treatments using a variety of approaches.

PluristemOn June 11, Pluristem Therapeutics of Haifa announced a multicenter Phase 2 US Food and Drug Administration (FDA) efficacy and safety study of its PLX-PAD cells for treating severe Covid-19 complicated by acute respiratory distress syndrome (ARDS).

PLX, an injected regenerative placenta-derived cell therapy, stimulates the immune systems natural regulatory T cells and M2 macrophages, possibly preventing or reversing a cytokine storm. PLX cells potentially reduce the incidence or severity of Covid-19 pneumonia and pneumonitis.

Pluristem has treated Covid-19 patients under compassionate use programs in the United States and Israel. Initial data from 18 patients showed that 75% were off mechanical ventilation within 28 days.

PLX cells are available off-the-shelf and once commercialized, can be manufactured in large-scale quantities, offering a key advantage in addressing a global pandemic, the company said.

SilkimJerusalem-based Silkim Pharma recently submitted Coronzot, its novel treatment for Covid-19 patients with moderate to severe symptoms, to the FDAs Investigational New Drug (IND) program.

IND designation would give Silkim permission to start human clinical trials and ship Coronzot across state lines before a marketing application has been approved.

Coronzots novel mechanism targets a pivotal factor in cytokine storms. It removes an inflammatory overaccumulation of labile iron and replaces it with a minute amount of gallium or zinc.

This not only suppresses the storm but also inhibits viral proteins that attack the lungs and heart. Gallium inhibits virus replication and promotes apoptosis (self-destruction) of already invaded cells. Zinc helps suppress inflammatory reactions and enzymes that enable coronavirus replication.

The company is actively engaged in the FDA process. We look forward to finalizing the IND and then moving towards conducting clinical studies of Coronzot for Covid-19, said Silkim Pharma CEO Dror Chevion.

RedHill BiopharmaRedHill Biopharma, based in Raleigh, North Carolina, and Tel Aviv, is racing to advance our development program with opaganib for Covid-19, according to a June 10 statement by Dr. Mark L. Levitt, RedHill medical director.

RedHill acquired opaganib from US-based Apogee Biotechnology, which developed this oral drug to fight cancer, inflammation, and viruses.

RedHill has seen encouraging preliminary findings from six Israeli Covid-19 patients given opaganib under compassionate use to reduce lung inflammation. All were weaned from supplemental oxygen and discharged from the hospital without having to receive mechanical ventilation.

RedHill plans a multicenter, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study on 270 US patients with severe Covid-19 pneumonia.

We are expanding the development program to Russia and additional European countries, parallel with the US clinical study, to accelerate the collection of robust data on the potential efficacy of opaganib against Covid-19, said Levitt.

The company is working with government agencies worldwide to allow more patients access to the investigational drug through clinical studies and compassionate use programs.

InnoCanInnoCan founders, from left, Ron Mayron, Iris Bincovich, Yoram Drucker. Photo by Rotem LahavInnoCan Pharma Israel and Tel Aviv University tech-transfer company Ramot are collaborating to develop a new CBD-loaded exosome technology to fight lung inflammation.

Exosomes, small particles created from stem cells, can act as homing missiles targeting specific damaged organs and facilitating cell-to-cell communication.

Combining the cell-healing properties of exosomes with the anti-inflammatory properties of the cannabis-derived compound CBD is expected to have a strong synergetic effect. The treatment is administrated by inhalation.

Stero BiotechsStero Biotechs of Bnei Brak has started a small clinical trial at Rabin Medical Center in Petah Tikva on the tolerability, safety, and efficacy of CBD-enhanced steroid treatment for hospitalized Covid-19 patients.

Steroid treatment is usually the first or second line of treatment for hospitalized patients. CBD enhances the therapeutic effect of steroid treatment and treats the bio-mechanism affected by the virus, the company explained.

Eybna and CannaSoulTwo Israeli cannabis R & D firms, Eybna Technologies and CannaSoul Analytics, develop a proprietary terpene formulation for modulating cytokine storms.

Terpenes are organic compounds found in cannabis and other plants. Studies suggest they can be effective antiviral agents.

CannaSouls Cytokine Storm Assay (from its Myplant-Bio subsidiary) will aid in optimizing and customizing Eybnas novel NT-VRL inhaled formulation for treatment and prevention of viral infections in high-risk populations and actively ill patients.

The FDA considers this assay as a good predictor for cytokine storm response and immunotoxicity, and it is commonly required in the development of biological treatments, according to CannaSoul Chairman and CSO Prof. Dedi Meiri.

The NT-VRL formulation intended to be used via inhalation, said Eybna CEO Nadav Eyal. This delivery method dramatically increases the terpenes bioavailability by directly contacting the infected cells in the respiratory system.

CannaSoul aims to identify other cannabis molecules capable of suppressing a cytokine storm in response to Covid-19 without completely suppressing the immune system. It is also studying how cannabis molecules could modulate the ACE2 receptor, which allows the virus to inject its genetic expression into human cells.

KamadaBased in Rehovot, Kamada has begun supplying its experimental plasma-derived Hyperimmune IgG therapy for compassionate use in severe Covid-19 cases in Israel.

The treatment is based on plasma donated by recovered Israeli Covid-19 patients. One critically ill patient at Hadassah Medical Center showed initial improvement after having the experimental IgG therapy but ultimately did not survive.

During the third quarter of this year, Kamada expects to start a Phase 1/2 clinical study in hospitalized Covid-19 patients in Israel and hold a pre-IND meeting with the FDA to expand clinical development in the United States in partnership with Kedrion Biopharma.

Kedrion is collecting plasma from recovered American Covid-19 patients at 23 FDA-approved centers across the United States. This will be used by Kamada to manufacture additional batches of the product.

To the best of our knowledge, Kamada is the first company globally to complete manufacturing of a plasma-derived IgG product for the treatment of Covid-19, said Kamada CEO Amir London.

Israel Institute for Biological ResearchThe government-run Israel Institute for Biological Research (IIBR) announced in May that analogs of two drugs for Gauchers disease proved effective against SARS-CoV-2.

This drug cocktail is made up of the FDA-approved Cerdelga and an analog of the second drug in advanced stages of the approval process.

The IIBR study on cell cultures demonstrated that the two-drug treatment significantly reduced the coronaviruss replication capacity and the destruction of the infected cell. This potential treatment is currently being tested in animals infected with the coronavirus.

The IIRB also isolated several critical coronavirus antibodies that successfully neutralized aggressive coronavirus in lab tests. These could form the basis of future treatment following further testing.

PepticomBased in Jerusalem, Pepticom computationally designs novel peptide drug candidates using artificial intelligence. The company raised $5 million last year.

Three months ago, Pepticom began implementing its proprietary AI technology on various coronavirus proteins to identify novel peptides that inhibit the interaction between the spike protein of SARS-Cov-2 and the ACE2 receptor thereby stopping the virus from entering the cell.

CEO Immanuel Lerner says three such proteins have already been identified and are being validated in the lab.

Using AI is a fast way to find these peptides, which are less expensive and easier to produce than antibodies, Lerner tells ISRAEL21c. Many parties are interested in looking at our results and finding ways to develop this further.

Bonus BioGroupIn April, Bonus BioGroup initiated a preclinical study of MesenCure, its unique drug for treating acute and life-threatening respiratory distress in coronavirus and pneumonia patients.

MesenCure consists of activated mesenchymal stromal (stem) cells from healthy adult donors. The activation of these MSCs is intended to boost their ability to reduce lung inflammation, promote regeneration of the diseased lung tissue, and alleviate respiratory and other symptoms in the lungs.

The development of MesenCure relies on more than a decade of related experience and technologies that Bonus BioGroup has used in developing its lead product, a tissue-engineered bone graft, also based on MSCs.

With the current coronavirus outbreak, Bonus BioGroup has started tissue culture studies into the potential of these MSCs, further activated, to alleviate inflammation, including in the lungs, and possibly attenuate the cytokine storm in COVID-19 patients, the company explained.

The preclinical study in several animal models is expected to be completed in the third quarter of 2020. The company said preliminary results indicate that following the treatment with MesenCure, the microscopic appearance of the treated lungs was similar to a healthy lung, and a significant improvement in additional related parameters was achieved.

Bonus BioGroup presented these results to 1,800 scientists, physicians, and public opinion leaders at the International Society for Cell & Gene Therapy virtual conference in May.

NanoGhostTechnion-Israel Institute of Technology Prof. Marcelle Machluf developed a drug-delivery technology that uses reconstructed mesenchymal stem cells as nano-vesicles to transport medicine directly to a target.

NanoGhost is the startup she established to commercialize the technology, which has proven successful in treating pancreatic, lung, breast, prostate, and brain cancer in mice. The NanoGhost technology has been patented in the United States and Europe, with additional patents pending in India and China.

Now, Machluf is adapting her technology to create decoy NanoGhosts that attract and entrap the coronavirus, making for a less severe infection. She explains it in the video below.

EnlivexEnlivex Therapeutics of Ness Ziona is developing Allocetra, a novel immunotherapy medication to treat organ dysfunction and acute multiple organ failure associated with sepsis and Covid-19, as well as solid tumors.

Allocetra rebalances a severely unbalanced immune system by engaging with the immune systems own regulation mechanisms. It is designed to restore a safe immune balance following a cytokine storm.

Enlivex is starting to recruit Covid-19 patients in Israel and in the United States to test the potential effect of Allocetra on moderate to severe cases. A patent from the Japan Patent Office is expected during the third quarter of 2020.

Weizmann Institute of ScienceOrganic chemist Nir London of the Weizmann Institute of Science in Rehovot is co-leading a collaborative project to identify small molecules that can bind to and inhibit a protease enzyme that the SARS-CoV-2 virus needs to reproduce.

London and his research team had previously developed an advanced method for identifying potential inhibitors for numerous proteins.

So far, we have made close to 800 compounds and tested more than 650 and keep getting closer to sufficiently potent inhibitors, London tells ISRAEL21c.

These inhibitors will be further investigated for their potential as a starting point for new drugs against the coronavirus.

London is working with researchers from Oxford University, Memorial Sloan Kettering Cancer Center, University of British Columbia, and Californian-based biotech company.

The Yucatan TimesNewsroom

comments

View post:
13 promising Covid-19 treatments emerging from Israel - The Yucatan Times

Read More...

With two research papers published, UW Oshkosh biologist has a whale of a week – UW Oshkosh Today

July 10th, 2020 4:48 pm

July is off to a good start academically speaking for Morgan Churchill, an assistant biology professor at the University of Wisconsin Oshkosh.

The vertebrate paleontologist is an author on not one but two research papers published this week in high-impact, peer-reviewed journals.

First, a paper that describes a new type of giant predatory dolphin fossil appeared Thursday in Current Biology, a biweekly scientific journal that emphasizes research on molecular biology, cell biology, genetics, neurobiology, ecology and evolutionary biology.

Second, a study that examined 172 toothed whale skulls to quantify cranial asymmetry and reconstruct the evolutionary history of the aquatic mammal was published today in BMC Biology, an open access journal featuring outstanding research in all areas of biology.

Ive never had this type of week before, said Churchill, who has taught undergraduate human anatomy at UWO since joining the biology faculty in 2017.

Both studies contribute to the understanding of whale and dolphin evolution, two closely related marine mammals. In fact, all dolphins are whales but not all whales are dolphins.

Whales capture our attention as they are very intelligent and have become the poster children for environmental causes and endangered species, he said. Whales also have an excellent fossil record, making them icons of evolution.

Churchills overall research program focuses on examining how marine mammal morphology has adapted to an aquatic lifestyle over time and how changes in morphology have influenced diversity and evolution in the group. Morphology is the study of size, shape and structure of animals, plants and microorganisms.

In the Current Biology article, Churchill and colleagues at the College of Charleston, New York Institute of Technology and Wellesley College report the nearly complete skeleton of the extinct large dolphin, Ankylorhiza tiedemani, from South Carolina.

This new specimen fills in important anatomical information on the early evolution of locomotion in whales, as well as reveals the ecological diversity in whales that was already present 24 million years ago, Churchill said.

As second author on the study, Churchill carried out the anatomical analyses and collaborated on interpreting the results and writing the paper.

Ankylorhiza is not a member of any group of whales living today but rather is closely related to the common ancestor of all toothed whales.

Evidence from its anatomy suggests it was an apex predator, perhaps filling a niche today occupied by the killer whale, Orcinus orca, Churchill said.

Ankylorhiza preserves a relatively primitive vertebral column and flipper, indicating that simplification of limbs and vertebrae evolved independently in baleen whales (also known as whalebone whales) and toothed whales.

The most important finding of this study is that we provide evidence that adaptations for underwater locomotion evolved separately in these two major groups of whales alive todaybaleen whales and toothed whaleslikely due to similar functional demands, Churchill said. This highlights an excellent example of convergent evolution, as well as reveals that whale evolution is much more complicated than we thought.

In addition, this new specimen shows that even early in their evolution, toothed whales showed a high degree of diversity with different species adapting to different lifestyles and diets, he said.

Toothed whales also have some of the most bizarre skulls of any mammal group, Churchill said.

Much of this weirdness is due to the high levels of bilateral cranial asymmetry present in the skull, he explained. In most animals, the bones that make up the face are the same size for both the right and the left halves of the skull. However, in many whales, bones on the right side of the face are much larger than those on the left.

Although remarkable, the feature has been poorly studied and not rigorously quantified in fossil whales.

For the study reported in the BMC Biology article, Churchill was part of a team of researchers led by Ellen Coombs from University College London and the Natural History Museum in London.

For his part, Churchill provided a large number of 3D scans of the whales collected from museums during a post-doctoral project.

The research showed that the cranial asymmetry is likely due to development of echolocationthe ability to locate objects by reflected soundin the toothed whales.

This research highlights a major evolutionary change in one of the best examples of evolution, Churchill said. It provides the first exhaustive quantification of cranial asymmetry in whales, traces its evolution and ties the changes with asymmetry to the development of new adaptations and changes in the environment.

Churchills research lab at UWO has been a training ground for undergraduate biology students. In fall 2020, a graduate student will be joining the team.

Learn more:

Go here to see the original:
With two research papers published, UW Oshkosh biologist has a whale of a week - UW Oshkosh Today

Read More...

Largest-Ever Study of Prostate Cancer Genomics in Black Men IDs Potential Targets for Precision Therapies – UCSF News Services

July 10th, 2020 4:48 pm

Black men in the United States are known to suffer disproportionately from prostate cancer, but few studies have investigated whether genetic differences in prostate tumors could have anything to do with these health disparities.

Now, in the largest study of its kind to date, researchers from Boston University School of Medicine (BUSM), UC San Francisco (UCSF), and Northwestern University have identified genes that are more frequently altered in prostate tumors from men of African ancestry compared to other racial groups, though the reasons for these differences is not known, the authors say. None of the individual tumor genetic differences that were identified are likely to explain significant differences in health outcomes or to prevent Black Americans from benefiting from a new generation of precision prostate cancer therapies, the authors say, as long as the therapies are applied equitably.

The newly identified gene variants could potentially lead to precision prostate cancer therapies specifically focused on men of African ancestry, and will inform broader efforts by the National Cancer Institutes RESPOND study to link gene variants to health outcomes in an even larger cohort of Black patients nationwide.

Despite declines in mortality related to cancer in the U.S., disparities by race have persisted. One in every six Black Americans will be diagnosed with prostate cancer in their lifetime, and these men are twice as likely to die from the disease as men of other races. But it is not yet clear to researchers whether differences in prostate cancer genetics contribute to these health disparities in addition to the social and environmental inequities known to drive poorer health outcomes across the board.

To date, studies trying to figure out what genes are commonly mutated in prostate cancers often have had very few samples from racial/ethnic minority groups despite the greater burden of prostate cancer in these populations. In May, the FDA approved a class of drugs known as PARP inhibitors as a therapy for men with prostate cancers driven by specific genetic mutations, but it is not known how prevalent these mutations are in people of African descent. As more genetic health studies are performed in minority populations, it has become clear that other genetically targeted therapies that have been developed based on studies of patients of European descent are at times much less effective, and in some cases cause dangerous side-effects, in other racial and ethnic groups.

In the new study, published July 10, 2020 in Clinical Cancer Research, a journal of the American Association for Cancer Research, the research team set out to better understand differences in the mutations driving prostate cancer tumors in men with African versus European ancestry, and whether any such differences could influence disease outcomes or the effectiveness of PARP inhibitors or other targeted therapies.

The researchers collected and analyzed DNA sequencing data from previously published studies and from a commercial molecular diagnostics company. In total, they examined mutational patterns in prostate cancers from more than 600 Black men, representing the largest such study of this population to date.

The team found that the frequency of mutations in DNA repair genes and other genes that are targets of current therapeutics are similar between the two groups, suggesting that at least these classes of current precision prostate cancer therapies should be beneficial in people of both African and European ancestry, according to corresponding author Franklin Huang, MD, PhD, an assistant professor in UCSFs Division of Hematology/Oncology and member of the UCSF Helen Diller Family Comprehensive Cancer Center, UCSF Institute for Human Genetics, and UCSF Bakar Computational Health Sciences Institute.

While the researchers found no significant differences in frequencies of mutations in genes important for current prostate cancer therapies, they did identify other genes, such as ZFXH3, MYC, and ETV3, that were more frequently mutated in prostate cancers from Black men.

"These results reinforce the idea that there can be biological differences in prostate cancers between different ancestral groups and that samples from Black Americans need to be included in future molecular studies to fully understand these differences," said co-corresponding author Joshua Campbell, PhD, assistant professor of medicine at BUSM.

The poorer health outcomes we see in Black men with prostate cancer are not easily explained by any of the distinct gene mutations we identified in prostate tumors from men of African ancestry. This highlights the need to examine the environmental and social inequities that are well known to influence health outcomes across the board, Huang added. On the other hand, our tumor genomic analysis also showed that current precision medicine approaches ought to be as effective in Black Americans as they have been for other groups if we can ensure that these drugs are applied equitably going forward."

Developing a comprehensive understanding of how tumor genomics and other biological factors interact with social and environmental inequities to drive poorer clinical outcomes for Black prostate cancer patients should be an important priority for the efforts to improve precision medicine for these patients, the researchers say.

These types of studies will remain important to understand when certain therapies may preferentially benefit Black patients, who continue to remain underrepresented in clinical trials, Campbell said.

In particular, the results will inform the efforts of the NCI-funded RESPOND Study. RESPOND provided funding for the new UCSF-BUSM-Northwestern study to guide its efforts to perform targeted gene sequencing in tumors from an even larger cohort of Black prostate cancer patients, said Huang, who leads RESPONDs tumor genetics studies based at UCSF. Through partnerships with Black communities across the country, RESPOND aims to recruit 10,000 Black prostate cancer patients in an effort to better understand the drivers of the diseases outsize burden among Black Americans.

"Previous studies have looked in isolation at different biological, social and environmental drivers ofwell-knownracial disparities in prostate cancer,Huangsaid. RESPOND is a nationwide effort to integrate all these components and ultimately identify specific steps that can be taken toeliminateprostate cancers unequal burden in Black communities.

Authors: The studys lead authors are Yusuke Koga of BUSM, Hanbing Song of UCSF, and Zachary Chalmers of Northwestern University. Additional authors are Elad Ziv of UCSF; Justin Newberg and Garrett M. Frampton of Foundation Medicine, in Cambridge; Eejung Kim and Daphnee Piou of the Broad Institute of MIT and Harvard; Jian Carrot-Zhang and Matthew Meyerson of the Broad Institute and Dana-Farber Cancer Institute; Paz Polak of Mt. Sinai School of Medicine in New York; and Sarki Abdulkadir of Northwestern University.

Funding: The study was supported by the U.S. Department of Defense (W81XWH-17-PCRP-HD); the U.S. National Institutes of Health (NIH) National Cancer Institute (NCI) (P20 CA233255-01, U19 CA214253); and the Prostate Cancer Foundation.

Disclosures: The authors declare no relevant conflicting financial interests.

About UCSF:The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwidethrough advanced biomedical research, graduate-level education in the life sciences and healthprofessions, and excellence in patient care. It includes UCSF Health, which comprises three top-ranked hospitals, as well as affiliations throughout the Bay Area.

About BUSM: Originally established in 1848 as the New England Female Medical College, and incorporated into Boston University in 1873, Boston University School of Medicine (BUSM) today is a leading academic medical center with an enrollment of more than 700 medical students and 950 students pursuing degrees in graduate medical sciences.BUSM faculty contribute to more than 950 active grants and contracts, with total anticipated awards valued at more than $693 million in amyloidosis, arthritis, cardiovascular disease, cancer, infectious diseases, pulmonary disease and dermatology, among other areas. The Schools teaching affiliates include Boston Medical Center, its primary teaching hospital, the Boston VA Healthcare System, Kaiser Permanente in northern California, as well as Boston HealthNet, a network of 15 community health centers. For more information, please visithttp://www.BUSM.bu.edu/busm/.

Go here to read the rest:
Largest-Ever Study of Prostate Cancer Genomics in Black Men IDs Potential Targets for Precision Therapies - UCSF News Services

Read More...

Growing Demand for Orf Expression Clones Market to Significantly Increase Revenues Through 2025 – 3rd Watch News

July 10th, 2020 4:48 pm

DNA is transcribe into messenger RNA, messenger RNA is translated into protein ORF. During translation, the combination of three nucleotide codons are required for protein synthesis. The nucleotide that starts translation and stops translation is known as ORF. Every DNA has six open reading frame and it is important to determine the correct open reading frame so that the protein is expressed properly. An Open Reading Frame starts with ATG (Met), which is known as start codon and ends with DNA sequence such as TAA, TAG, TGA known as stop codon. ORF clones are eliminates the wearisomesteps of RNA isolation, DNA synthesis, PCR amplification and other tedious sequencing and validation procedures.

To remain ahead of your competitors, request for a sample [emailprotected] https://www.persistencemarketresearch.com/samples/19597

The ORF expression clones are plasmid that contains protein coding DNA, the DNA contains the coding sequence without 5 and 3 end untranslated regions. The ORF expression clones helps to save as it moves directly protein expression and protein analysis. The ORF clones aids to get protein expression and analysis faster. The ORF allows to get gene of interest and expressed protein quickly, and help researchers to conduct clinical and medical applications. Clinical laboratory are highly equipped with assay and instrument systems used for the detection and classification of various disease type such as cancer and risk of cancer progressions, cardiovascular diseases, and others. The advancement in the molecular genetics, bioinformatics, proteomics, increasing number of infection rate is prompting manufacturers to seek newer methods of research, has led to the revenue growth over the forecast period.

Increased demand for research and development for early detection and diagnosis of disease, increased expenditure on healthcare sector, growing number of hospitals and diagnostic laboratories, increased demand for personalized medicines requires the study of individual cell structure and function, rise in prevalence of cell based diseases such as cancer and autoimmune diseases requires the detection and diagnosis of specific cell and tissue, rise in number of biopsy procedures. Technological advancement in the diagnostic and treatment process of infectious diseases, advancement in molecular techniques are the factors fueling the demand of ORF expression clone market in the near future.

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/19597

The global ORF expression clones market is segmented on basis of expression system,application, end user and geography

Segment by Expression System

Segment by Application

Segment by End User

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/19597

Global ORF expression clones is segmented by expression system, application and end user. On the basis of expression system the, ORF expression clones market is segmented as mammalian expression system, lentiviral expression system, bacterial expression system, yeast expression system, insect, wheat germ cell and others. Based on the application type, global ORF expression clones market is segmented as recombinant protein expression, functional assays, protein characterization, In vitro transcription and other application for research and study purpose. On the basis of end user, the global ORF expression clones market is segmented into biotechnological companies, pharmaceutical companies, contract research organizations, academic/ research institutes. Increasing outsourcing by pharmaceutical and biotechnological companies, declining R&D productivity and patent cliff sales drop leading to increasing research intensity in the pharmaceuticals sector, rapid process/product development due to fewer steps, increased awareness about new product launch and others are some of the factors drive the global ORF expression clones market during the forecast period. Whereas high cost and short reaction scale, low protein expression, inadequate access to health care, lack of standardized tools for research and development are some of the factors that may hamper the growth of global ORF expression clones market.

By Geography, the global ORF Expression Clones market is segmented into five broad regions viz. North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. North America is estimated to lead the global ORF expression clones market due to increasing focus on protein expression and production, growing demand for simple and efficient protein production methods, government funding for research and development in developed countries and others. Europe market is also projected to experience high growth due to emphasis on up-scaling and industrial application in the near future. Asia Pacific market is anticipated to grow at the fastest growth rate during the forecast period, owing to factors such as focusing on healthcare expenditures, rise in research and development facilities and others.

Some of the major players in global ORF expression clones market are

The rest is here:
Growing Demand for Orf Expression Clones Market to Significantly Increase Revenues Through 2025 - 3rd Watch News

Read More...

"Glen Mor; the new raspberry that gives more" – hortidaily.com

July 10th, 2020 4:48 pm

Among the three new raspberry varieties James Hutton Limited has released to soft fruit growers in 2020, Glen Mor is the floricane raspberry variety the industry has been waiting for, with genetic marker Rub118b conferring resistance to raspberry root rot, Phytophthora Rubi.

Root rot is one of the most serious raspberry diseases. Impossible to eradicate from infested soils, root rot has prompted the move to growing in pots, which are sometimes raised above the soil below as double protection from the pathogen.

Breeding for root rot resistance has long been a major objective of raspberry breeding at the James Hutton Institute. Dr Julie Graham has spent over a decade developing the first genetic linkage map for raspberry and subsequently identifying molecular markers to link important traits to genetic regions. Deployed early in the breeding process this has helped to speed the release of new varieties. Julies group identified the genetic regions significantly associated with raspberry root rot and developed a molecular marker that can be used in the James Hutton Limited breeding programme to quickly and effectively identify selections with likely resistance.

In James Hutton Institute trials, plants of Glen Mor have spent six years in a soil plot infested with root rot and have shown no symptoms of the disease, despite flooding over several seasons but, root rot resistance is not the only thing that Glen Mor has to shout about. Selected for release by the 2014-2019 tranche of the James Hutton Limited Raspberry Breeding Consortium; a partnership of marketing and grower groups, propagators, AHDB and Scottish Government, that funds the breeding programme to create new, targeted raspberry varieties, Glen Mor has been fast tracked from the breeding programme due to both outstanding trial results and retailer feedback.

Glen Mor has outstanding fruit quality, yield and flavour and due to its size and presentation, is economical to pick. Its large fruit size made choosing a name easy; Mor translates in old Scots as large, big or great.Glen Mors flavour is described by breeder, Nikki Jennings, as, Fruity and sweet, but with a balance of acid and notes of coconut.

Glen Mor is the result of a floricane x primocane cross and has benefits from both growth habits, including a lower chill requirement compared with other floricane varieties. Glen Mor also produces straight, spinefree long cane with a short internode length which makes it productive and easy to manage. Glen Mors excellent shelf-life score goes hand in hand with fantastic retailer feedback.

Speaking about Glen Mors release, Nikki says, We are very excited to release Glen Mor as our first variety with the root rot marker, combining resistance with superior commercial quality. Root rot resistance offers growers the option to return to soil production which makes plants much easier to manage at a lower cost.

Testing for the for Rub118b marker is now standard for promising seedlings from the James Hutton Limited breeding programme. Glen Mor plants are available now from RW Walpole and Genson BV in the EU, and from Global Plant Genetics and Meiosis in select territories out with the EU.

More technical information about Glen Morcan be found here.

Source: James Hutton.

Excerpt from:
"Glen Mor; the new raspberry that gives more" - hortidaily.com

Read More...

Largest study of prostate cancer genomics in Black Americans ids targets for therapies – Newswise

July 10th, 2020 4:48 pm

Newswise Black men in the United States are known to suffer disproportionately from prostate cancer, but few studies have investigated whether genetic differences in prostate tumors could have anything to do with these health disparities.

Now, in the largest study of its kind to date, researchers from Boston University School of Medicine (BUSM), UC San Francisco (UCSF), and Northwestern University have identified genes that are more frequently altered in prostate tumors from men of African ancestry compared to other racial groups, though the reasons for these differences is not known, the authors say. None of the individual tumor genetic differences that were identified are likely to explain significant differences in health outcomes or to prevent Black Americans from benefiting from a new generation of precision prostate cancer therapies, the authors say, as long as the therapies are applied equitably.

The newly identified gene variants could potentially lead to precision prostate cancer therapies specifically focused on men of African ancestry, and will inform broader efforts by the National Cancer Institute's RESPOND study to link gene variants to health outcomes in an even larger cohort of Black patients nationwide.

Despite declines in mortality related to cancer in the U.S., disparities by race have persisted. One in every six Black Americans will be diagnosed with prostate cancer in their lifetime, and these men are twice as likely to die from the disease as men of other races. But it is not yet clear to researchers whether differences in prostate cancer genetics contribute to these health disparities in addition to the social and environmental inequities known to drive poorer health outcomes across the board.

To date, studies trying to figure out what genes are commonly mutated in prostate cancers often have had very few samples from racial/ethnic minority groups despite the greater burden of prostate cancer in these populations. In May, the FDA approved a class of drugs known as PARP inhibitors as a therapy for men with prostate cancers driven by specific genetic mutations, but it is not known how prevalent these mutations are in people of African descent. As more genetic health studies are performed in minority populations, it has become clear that other genetically targeted therapies that have been developed based on studies of patients of European descent are at times much less effective, and in some cases cause dangerous side-effects, in other racial and ethnic groups.

In the new study, published July 10, 2020 inClinical Cancer Research, a journal of the American Association for Cancer Research, the research team set out to better understand differences in the mutations driving prostate cancer tumors in Black Americans compared to European Americans, and whether any such differences could influence disease outcomes or the effectiveness of PARP inhibitors or other targeted therapies.

The researchers collected and analyzed DNA sequencing data from previously published studies and from a commercial molecular diagnostics company. In total, they examined mutational patterns in prostate cancers from more than 600 Black men, representing the largest such study of this population to date.

The team found that the frequency of mutations in DNA repair genes and other genes that are targets of current therapeutics are similar between the two groups, suggesting that at least these classes of current precision prostate cancer therapies should be beneficial in people of both African and European ancestry, according to corresponding author Franklin Huang, MD, PhD, an assistant professor in UCSF's Division of Hematology/Oncology and member of the UCSF Helen Diller Family Comprehensive Cancer Center, UCSF Institute for Human Genetics, and UCSF Bakar Computational Health Sciences Institute.

While the researchers found no significant differences in frequencies of mutations in genes important for current prostate cancer therapies, they did identify other genes, such as ZFXH3, MYC, and ETV3, that were more frequently mutated in prostate cancers from Black men.

"These results reinforce the idea that there can be biological differences in prostate cancers between different ancestral groups and that samples from Black Americans need to be included in future molecular studies to fully understand these differences," said co-corresponding author Joshua Campbell, PhD, assistant professor of medicine at BUSM.

"The poorer health outcomes we see in Black men with prostate cancer are not easily explained by any of the distinct gene mutations we identified in prostate tumors from men of African ancestry. This highlights the need to examine the environmental and social inequities that are well known to influence health outcomes across the board," Huang added. "On the other hand, our tumor genomic analysis also showed that current precision medicine approaches ought to be as effective in Black Americans as they have been for other groups -- if we can ensure that these drugs are applied equitably going forward."

Developing a comprehensive understanding of how tumor genomics and other biological factors interact with social and environmental inequities to drive poorer clinical outcomes for Black prostate cancer patients should be an important priority for the efforts to improve precision medicine for these patients, the researchers say.

"These types of studies will remain important to understand when certain therapies may preferentially benefit Black patients, who continue to remain underrepresented in clinical trials," Campbell said.

In particular, the results will inform the efforts of the NCI-funded RESPOND Study. RESPOND provided funding for the new UCSF-BUSM-Northwestern study to guide its efforts to perform targeted gene sequencing in tumors from an even larger cohort of Black prostate cancer patients, said Huang, who leads RESPOND's tumor genetics studies based at UCSF. Through partnerships with Black communities across the country, RESPOND aims to recruit 10,000 Black prostate cancer patients in an effort to better understand the drivers of the disease's outsize burden among Black Americans.

"Previous studies have looked in isolation at different biological, social and environmental drivers of well-known racial disparities in prostate cancer," Huang said. "RESPOND is a nationwide effort to integrate all these components and ultimately identify specific steps that can be taken to eliminate prostate cancer's unequal burden in Black communities."

###

About UCSF:The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes UCSF Health, which comprises three top-ranked hospitals, as well as affiliations throughout the Bay Area. Learn more athttps://www.ucsf.edu, or see our Fact Sheet.

About BUSM:Originally established in 1848 as the New England Female Medical College, and incorporated into Boston University in 1873, Boston University School of Medicine (BUSM) today is a leading academic medical center with an enrollment of more than 700 medical students and 950 students pursuing degrees in graduate medical sciences. BUSM faculty contribute to more than 950 active grants and contracts, with total anticipated awards valued at more than $693 million in amyloidosis, arthritis, cardiovascular disease, cancer, infectious diseases, pulmonary disease and dermatology, among other areas. The School's teaching affiliates include Boston Medical Center, its primary teaching hospital, the Boston VA Healthcare System, Kaiser Permanente in northern California, as well as Boston HealthNet, a network of 15 community health centers. For more information, please visithttp://www.BUSM.bu.edu/busm/.

Continue reading here:
Largest study of prostate cancer genomics in Black Americans ids targets for therapies - Newswise

Read More...

Focusing on the common good in town hall, Yale leaders look toward fall – Yale News

July 10th, 2020 4:48 pm

President Peter Salovey and fellow campus leaders convened a virtual town hall July 9, pointing the way forward as Yale charts its course for the coming academic year.

The hour-long livestreamed event, the second of two scheduled presidential town halls, touched on a host of topics, including campus health and safety measures, asymptomatic COVID-19 screening, child care, work-study arrangements, shuttle bus services, thecancellation of fall sports, and the federal governments recent directive regarding international students.

Above all, Salovey said, the Yale community must pull together in a socially-distanced way to preserve public health while also holding true to Yales mission of teaching and research.

Teaching and learning. Scholarship and research. These are essential to Yale being Yale, Salovey said. Im asking each of you, personally, for your help.

Arecording of the eventis posted on the presidents website.

Extensive details about the universitys plans for the 2020-21 academic year are available on itsmain COVID-19 website.

Joining Salovey for the town hall were Scott Strobel, provost and Henry Ford II Professor of Molecular Biophysics and Biochemistry; Nancy Brown, the Jean and David W. Wallace Dean of the Yale School of Medicine and C.N.H. Long Professor of Internal Medicine; Jack Callahan Jr., senior vice president for operations; Marvin Chun, dean of Yale College and the Richard M. Colgate Professor of Psychology; Lynn Cooley, dean of the Graduate School of Arts and Sciences and C.N.H. Long Professor of Genetics; Tamar Gendler, dean of the Faculty of Arts and Sciences and Vincent J. Scully Professor of Philosophy; and Kim Goff-Crews, secretary and vice president for university life.

Together, Yales leaders fielded more than 30 representative questions, taken from more than 900 submitted by 600 members of the Yale community before and during the event. Most questions sought amplification or clarification ofdecisions announced on July 1, when Yale invited students to return for the 2020-21 academic year.

First-year students, juniors, and seniors may be on campus for the fall semester; sophomores, junior, and seniors for the spring semester. Graduate and professional school students may return for the full year.

Undergraduates have the option of taking a leave of absence or gap year. Those first-year and sophomore students who enroll for both semesters of the upcoming academic year, including a remote semester, have the option of taking two free courses in Yale Summer Session 2021.

Yale will conduct mandatory COVID-19 testing for all students, who will further be required to sign a community compact pledging to follow university and public health guidance and protocols such as social distancing and wearing protective masks.

During the town hall, Salovey said Yale will announce specific enforcement measures for the community compact by the end of August.

This is a moment when we can all focus on the common good, he said.

Yale aims to announce its plans for the spring semester by early November, he said.

Salovey also stated vigoroussupport for Yales international students, noting that Yale will join an amicus brief in a lawsuit against the U.S. Department of Homeland Security regarding a recent policy that would potentially keep many such students from studying at U.S. universities.

Calling the policy deeply troubling, the president said Yales hybrid plan to conduct both online and in-person classes meets DHS requirements.

Strobel fielded several questions relating to child care, tuition, and travel for researchers doing field work.

We recognize these challenges are great, the provost said, acknowledging that many members of the Yale community are balancing work and child care responsibilities. Strobel said Yale has extended its benefits for child care options.

Strobel said Yale is not offering tuition reduction for the coming year, but said room and board costs will be lower than usual due to the adjusted academic calendar. And he noted the availability of the free summer courses.

As for fieldwork, Strobel said researchers whose projects require travel may request an exception to Yale travel restrictions now in place.

Many questions at the town hall centered around Yales efforts to ensure public health and safety.

Brown said Yale will continue to follow all national, state, and local guidance regarding COVID-19. In addition, she said Yale is tracking trends in new COVID-19 cases and monitoring rates of infection.

Yale is lowering risk of infection for students, faculty, and staff by reducing the density of people in classrooms, labs, libraries, and residential colleges, the medical school dean said. This includes upgrading certain ventilation systems, stepping up cleaning protocols, and adjusting the flow of foot traffic inside buildings.

Brown said the required COVID-19 screening will be more frequent for undergraduates than for graduate students because undergraduates typically live in closer proximity. She said Yale is conducting some of its screening with shorter nasal swabs, which can be self-administered under the supervision of a health care professional.

Details of Yaleshealth and safety guidelinesare available online.

Chun answered several questions about student life on campus for the 2020-21 academic year.

He said priority for on-campus attendance went to Yale College seniors, because this will be their final year on campus. Juniors were also invited to be on campus for the full year, he said, because junior year is a pivotal year for students to deepen work in their majors.

Yales cultural centers and most campus facilities will be open, Chun said; undergraduates will have the opportunity to conduct research on campus and remotely; students taking a semester or the full year off will not be able to participate in work study due to federal rules, but will have access to Yale career services.

Chun said students who take a semester or year off will be allowed to take part in commencement ceremonies with their original class.

He also assured students that public safety measures will allow for camaraderie, socializing, and the daily ebb and flow of campus life, even if daily routines are different.

You will be able to fully interact with your amazing friends, he said.

Goff-Crews said departments across Yale will directly address issues of inclusion and diversity, and that related events will be announced this summer. Yales support of Black, brown, Asian, and LGBTQ students, faculty, and staff is of paramount importance, she said.

She added that Yale is in the process of updating campus policing policies, including who will respond to emergency calls unrelated to criminal activity.

Several town hall questions focused on faculty recruitment and teaching.

Gendler said Yale remains fully engaged in recruiting and retaining premier faculty. She said new faculty hires will reflect Yales commitment to faculty diversity and excellence, key academic priorities, and the recruitment of the next generation of talented scholars. The university will offer an exceptional student-faculty ratio.

Gendler said Yale is supporting faculty during the pandemic by, among other things, providing innovative online teaching guidance through the Poorvu Center for Teaching and Learning and by matching faculty who need research support with graduate students in need of research opportunities.

Gendler also highlighted the learning environment students will experience this year. Many faculty across campus are adding extra sessions of the most popular classes, developing creative ways to have small-group interactions, and inviting an array of authors, composers, and experts to take part in teaching activities.

The individual attention students will get will be extraordinary, Gendler said.

At the end of the town hall, Salovey encouraged students, faculty, and staff to follow updates on YaleNews and Yales COVID-19 website throughout the summer.

To fight COVID-19, we need to do it as a unified community, he said. Thats what Yale is all about.

See more here:
Focusing on the common good in town hall, Yale leaders look toward fall - Yale News

Read More...

Lung Cancer in Non-smokers May Respond Differently to Treatment – Technology Networks

July 10th, 2020 4:48 pm

Lung cancer in non-smokers is a diverse and distinct disease from that in smokers, and is likely to respond differently to targeted treatments, a major new study shows.Scientists studied a population in Taiwan with high rates of lung cancer among non-smokers and found a range of genetic changes which varied depending on a patients age or sex.

Many non-smokers with lung cancer had signs of DNA damage from environmental carcinogens, with young women in particular having particular genetic changes which are known to drive cancer to evolve aggressively.

The study which was co-led by scientists at The Institute of Cancer Research, London, alongside colleagues in Taiwan could lead to new treatments for non-smokers with lung cancer tailored to the newly identified genetic changes.

The research, published in the prestigious journal Cell today (Thursday), is the most comprehensive ever study of the biology of lung cancer in non-smokers. It was funded by Cancer Research UK and various institutions in Taiwan including the Ministry of Science and Technology.

Scientists at The Institute of Cancer Research (ICR) worked with colleagues at the Academia Sinica and the National Taiwan University to analyse tumour samples from 103 lung cancer patients from Taiwan the majority of whom were non-smokers.

Around 10-15 per cent of lung cancers in the UK occur in people who have never smoked but in East Asia, the proportion of lung cancers that occur in non-smokers is much higher, especially among women.

The researchers conducted a detailed analysis of genetic changes, gene activation, protein activity and cellular switches in lung cancer to develop the most comprehensive overview of the biology of disease in non-smokers to date.

Looking at the genetics and the related proteins produced by cancer cells in the tumour samples, scientists found that some early-stage lung tumours in non-smokers were biologically similar to more advanced disease in smokers.

Tumours in women often had a particular fault in the well-known lung cancer gene EGFR, whereas in men the most common faults were in the KRAS and APC genes. These differences could affect the response to targeted drugs in men and women.

Picking out people with late-like early-stage lung tumours could help guide treatment decisions, and patients could be monitored more closely for signs of their disease progressing.

The study found a pattern of genetic changes involving the APOBEC gene family in three-quarters of tumours of female patients under the age of 60, and in all women without faults in the EGFR gene.

APOBEC proteins play an important role in the function of the immune system but they can be hijacked by cancers, speeding up evolution and the emergence of drug resistance, a key area of study in the ICRs new Centre for Cancer Drug Discovery.

Patients without EGFR faults tend to do better on immunotherapy, and so testing for APOBEC could help pick out women more likely to respond to this form of treatment.

The team also picked out groups of patients particularly among older women whose cancers had mutation patterns linked to cancer-causing substances in their environment such as pollutants.

Finally, the team identified 65 proteins that were overactive in lung tumours that matched with existing candidate drugs. They found that one protein that cuts away at the surrounding tissue, called MMP11, was linked to poorer survival and could be explored as a marker for early detection.

While the new study looked at patients treated in Taiwan, the researchers believe that many of their findings could be applicable to UK patients. Next, they will be validating their findings in larger studies and beyond Asia.

Dr Jyoti Choudhary, Team Leader in Functional Proteomics at The Institute of Cancer Research, London, said:

We carried out the most comprehensive study ever conducted into the biology of lung cancers in an East-Asian population with a high proportion of non-smokers, and found that their disease is molecularly diverse, and distinct from what we classically see in smokers.

We found distinct patterns of genetic faults in non-smokers and between women and men, which suggest that a woman who has never smoked, for example, is likely to respond differently to treatment than a male smoker.

Some early-stage lung tumours had molecular features that are much more like that typically seen in later-stage disease which could help us more accurately diagnose patients with aggressive disease, and inform treatment strategies.

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

This new study offers a deep dive into the biology of lung cancer in people who have never smoked. It reveals new ways of telling apart patients with different tumour characteristics that could be exploited with tailored treatment strategies.

Lung cancer is the biggest cancer killer in the UK, and much of what we know about the disease comes from studies in smokers. Im hopeful that the new insights gleaned in this new study will really step up precision medicine in lung cancer for non-smokers, so they can be offered smarter, kinder treatment options.

Dr Emily Armstrong, research information manager at Cancer Research UK, said:

In order to beat cancer, we need to understand all the ways it can develop. This research highlights just how much cancers can vary between people depending on their lifestyle and environment. Understanding the difference between lung cancers in smokers and non-smokers could be vital for providing patients with the most appropriate treatment.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

View post:
Lung Cancer in Non-smokers May Respond Differently to Treatment - Technology Networks

Read More...

Self-soothing strategies to help break a chain of anxious thoughts quickly – CBC.ca

July 10th, 2020 4:47 pm

It's an unprecedented time in our lives, and many of us are dealing with feelings of great uncertainty about our individual futures and the future of our world. We're learning to adjust to new schedules, and seeking ways to handle a deluge of new information and cope with life changes.

Anxiousness may arise as a normal reaction to this, and when our challenges feel overwhelming, chains of anxious thoughts can lead us to feeling hopeless and negative. Anxiety can also manifest in the body.

To help address anxiety when it arises, we invited two experts, Dr. Ana Bodnar, a registered clinical psychologist, and yoga and meditation teacher, and Pradeep Kumar, a former physician who teaches integrative mind/body medicine and meditation courses, to share simple and effective practices that can neutralize anxiousness and soothe in the moment.

"Rumination, in the form of repetitive thoughts, is often aligned with anxiety," says Bodnar. "Anxiety has a cyclical pattern that, if not interrupted, will run its course." Here are some techniques to interrupt anxious thoughts.

Positive self-talk

Bodnar describes positive self-talk as an intervention that can bring the mind back to reality in a safe and caring way. "A simple way to reduce anxiety is to use your internal voice to address what is happening and to acknowledge that there is an end within reach," she says.

Kumar says that we can even interrupt anxious thought patterns while we stay present in a conversation. "[Self-talk] breaks the anxiety cycle and helps you to release the rumination of the thoughts you are holding on to, allowing you to stay present and focused."

Bodnar suggests reciting these positive phrases:

"Even if I am feeling anxiety right now, it will pass.""Even if this feels uncomfortable right now, it will come to an end soon.""I can cope; I have been through difficult situations before.""I am more than my anxiety; it is a state that will pass."

If an experience starts to become overwhelming, it could also be appropriate to remove yourself from the situation, if possible, until you can bring yourself back into a state of comfort and ease, says Bodnar.

It's also important to recognize that anxiety is different from having a panic attack. "A panic attack can be an intense experience that may require counsel for appropriate care and treatment," Bodnar says.

The body scan

The body scan helps move the mind out of the thinking process and into the sensing process, says Bodnar, offering reality as a foundation to concentrate on. "The practice of focusing on your senses and body can draw your mind to the present moment and help stabilize anxiety by connecting [you] to what is happening right in front of you, instead of focusing on the anxiety itself."

The body scan should start from the ground up. "This will help to anchor your senses," she says, when you feel as if "they are slipping away with a spinning mind." When practiced with a long, deep inhalation and exhalation of equal ratio (known as "sama vritti" in the practice of yoga), this practice becomes most effective.

Focus on your breath.Begin sensing the ground under your feet.Recite internally, I am aware that my feet are the ground.Feel your toes on the ground.Recite internally, I am aware that my toes are on the ground.Slowly begin to observe your surroundings.Feel the texture of your clothing. Feel your calves and your thighs. Feel yourself sitting down.Recite internally, I am aware of the chair supporting me.Feel the tips of your fingers.Recite internally, I am aware of the tips of my fingers.Feel your back and neck relaxed. Feel the breath slowly moving into the abdomen and the chest.Recite internally, I am aware of my breath.Notice the sensation of the breath in the nostrils.Recite internally, I am aware of the sensation of my breath.Notice the saliva in your mouth.Recite internally, I am aware of the saliva in my mouth.Notice your body temperature.Recite internally, I am aware of my body temperature.Look around and slowly notice what you are seeing. Notice what you are hearing. Soften your eyes and focus on the breath.

Practice, focusing on your sensory awareness, and breathe with slow, long inhalations and exhalations. If you need to scan the body again, begin at the feet and work your way up the body.

Repeating mantra

The repetition of a mantra allows the mind to focus on one sound and can interrupt anxious thought patterns. "Repeating short, positive phrases, mantra or humming activates the relaxation response, as in meditation," says Kumar.

He mentions that if you practice a faith, prayer could be an option here as a focused intention of positive thought. However, "mantra [repetition], in particular, stimulates the vagus nerve, which helps to reduce the activity of the sympathetic nervous system, enabling a person to better deal with the stress and anxiety. Mantra practice also helps to bypass the amygdala activation in the brain, which is responsible for the fear and anger response, in turn, reducing anxiety."

Mindful action

Mindfulness consists of gently becoming aware of our thoughts, feelings, bodily sensations and environment through a compassionate and observational lens. It has long been used to reduce stress and anxiety, and to cultivate focus and clarity. Cognitive behavioural therapy interventions, for instance, often encourage being mindful of one's senses to address anxiety.

"Connecting to our senses is very grounding, and can quickly break the anxiety cycle and bring us back to our own centre," Bodnar says. She points out that mindfulness can be applied to any situation: walking, listening to others, preparing a meal. It's about being focused and truly engaging in whatever activity that we are involved in. For example, "eat mindfully," Bodnar says. "[Become] aware of the smell, colour [and] texture, and then taste the food. Eat slowly and savour the food."

"Deep breathing helps to retain carbon dioxide in the body and dilates blood vessels in the brain, inducing a hibernation-like state along with the increased secretion of endorphins and other neuro-chemicals to calm down the body and mind," Kumar explains. "Plus, it assists with the absorption of the nitric oxide gas molecules in the body to dilate the blood vessels, which helps in reducing the blood pressure."

Here are a few self-soothing breathing practices that can be used anywhere, at any time.

Slow, deep breathing

For this practice, Kumar says, simply breathe in and out slowly.You may breathe in for a count of 6 and breathe out for a count of 6.Repeat this 10 times.

The box breath

Bodnar recommends the box breath, a simple technique that aims to create relaxation by directing the breath using an equal inhalation to exhalation ratio. For this practice, the abdomen will rise as you inhale through the nose and deflate as you exhale through the nose. Do not breathe through the mouth.

Begin by becoming aware of your breath.Slowly and gently begin to lengthen and deepen your breath.Breathe into the abdomen, feeling the belly expanding outward.After a few deep and slow breaths, you will begin to count with the breath to regulate the length of the inhalation and exhalation.Inhale through the nose with a long, slow count of 2.Exhale through the nose, with a long, slow count of 2.Repeat the long, slow count of 2 for the inhale and the exhale until you feel the body and mind begin to relax, and that your breathing has become a gentle, equalized pattern.

"One way to look at anxiety is as energy that is out of balance. Since anxiety can have many physical expressions, physical movement can be very helpful in releasing anxiety," says Bodnar. Movement can include walking outside, working out, a yoga class, a simple stretching exercise, or you can put on your favourite music and dance.

"Physical techniques help more than the mental techniques in acute anxiety because a person can't concentrate on thoughts or emotions," says Kumar. "Simple interventions used to interrupt anxiety can create a shock-like effect in the nervous system to break the existing pattern of a strong emotional state."

Here are some options for movement practices to break the loop of anxiety.

Nature walks

If you're able to access nature while abiding by physical distancing guidelines, it can be a safe haven with many health benefits. "At a time when we are being asked to be more self-reliant, we can turn nature into a place of refuge and grounding," says Bodnar. She notes that this can be as simple as walking around your block and being mindful of the trees, the sky, the birds. "Stopping to really look at a tree and remembering how solid it is, with roots in the Earth, can also be helpful."

Muscle relaxation

"Muscle relaxation first stimulates the sympathetic nervous system and then auto-resets into the parasympathetic nervous system [to create] a state of relaxation," says Kumar. Here, he describes a simple and accessible practice that can be done anywhere and only takes a few minutes:

Make a tight fist and then relax the fist.Repeat five times.Close the eyes tightly then relax them.Repeat five times.

A longer practice is progressive muscle relaxation, which includes tensing and releasing all parts of the body to bring about a state of deep relaxation.

Exhalation with movement

In addition to deep breathing, Kumar describes a way to release anxiety by aligning the breath with an outward movement:

Throw the hands forward with an exhale, as if throwing the anxiety away from you. (This releases the energy of anxiety accumulated in the body.)

Repeat 10 times.

Firmly patting the body

"Sudden stimulation of the nerves breaks the existing thought pattern of anxiety," says Kumar. "The firm sensation of touch [also] increases the blood flow and stimulates the parasympathetic nervous system."

He says that you can simply, "open the palms and pat the head, shoulders, chest, belly, thighs and knees." You can also firmly rub the crown, chest and belly 10 times clockwise and 10 times counterclockwise.

Clapping your hands

A quick shift of emotional state can also occur from light pressure combined with an impactful sound. "Clapping stimulates acupuncture points in the palms and refocuses your attention. The body will be suddenly activated, and the sound and touch will break the cycle of thought or any strong emotional state," says Kumar.

Clap your hands 10 times.

Stamping your feet

"Stamping your feet similarly stimulates reflexology points in the feet and grounds the body into a calm state," says Kumar.

Stamp your feet 10 times.

Nicole Mahabir is the founder and director of JAI Wellness, a platform for health education, mindful living and well-being. For the past 10 years, Nicole has led professional IAYT-, YA- and EBNMP-certified programs, teaching nutrition, meditation, Ayurveda, yoga therapy and natural, anti-aging beauty. When she isn't teaching, Nicole creates integrated, sustainable health protocols for her busy clients, and leads corporate and wellness retreats. Follow Nicole on Instagram @jaiwellness or visit her website: jaiwellness.com.

Read more here:
Self-soothing strategies to help break a chain of anxious thoughts quickly - CBC.ca

Read More...

Wellness specialists from Rancho La Puerta and The Farm to host virtual masterclass on healing journeys – Spa Opportunities

July 10th, 2020 4:47 pm

Healing Hotels of the World is hosting a virtual Master Class with wellness experts from luxury destination spas, Rancho la Puerta and The Farm at San Benito.

Sarah Livia Brightwood, president of Rancho La Puerta in Mexico, and Dr Marian Alonzo, medical chief at The Farm at San Benito in the Philippines, will share their wisdom during a 45-minute Zoom session.

The two women will detail what a typical healing guest journey looks like at each of their wellness destinations and discuss what guests need and want right now when it comes to healing.

Brightwood is the daughter of Rancho La Puertas founders, Edmond Bordeaux Szekely and industry figure, Deborah Szekely, and her love of the earth has shaped her lifes work.

In addition to her role as president, she cares for 80 acres of gardens at the Ranch, which she created 30 years ago and has nourished to their present state.

She is also President of Fundacin La Puerta, through which she guides Rancho La Puerta's non-profit work in the region, and in 2007, she designed and opened La Cocina Que Canta at the Ranch, a culinary center and cooking school dedicated to teaching healthy eating.

Dr Alonzo serves as medical chief at The Farm at San Benito, and is an integrative medicine specialist. She is passionate about the principles that connect different streams in healing, including art therapy, behavioural biochemistry and healing movement.

She also researches the science of miracles and the energetic flows between different bodily organs to support the medical management of modern-day lifestyle illnesses, including autoimmune diseases, pre-psychiatric mental-emotional concerns, recovery from trauma and chronic pain management.

We are so privileged to have these two strong, insightful women to share their insight with us, says Elisabeth Ixmeier, co-founder of Healing Hotels of the World.

Both Rancho La Puerta and The Farm at San Benito are true healing destinations, and the combined wisdom and knowledge that Sarah Livia and Dr Marian possess is truly amazing.

The session is free, and will take place on Tuesday 14 July from 4:00- 4:45 pm (UTC), to sign up and receive log-in details, participants must RSVP beforehand to [emailprotected]

See the original post:
Wellness specialists from Rancho La Puerta and The Farm to host virtual masterclass on healing journeys - Spa Opportunities

Read More...

CB2 Insights to Host Q1 2020 Earnings Call on July 15, 2020 – Stockhouse

July 10th, 2020 4:46 pm

TORONTO, July 08, 2020 (GLOBE NEWSWIRE) -- CB2 Insights Inc. (CB2” or the Company”) (CSE: CBII; OTCQB: CBIIF), will be hosting its Q1 2020 earnings call on Wednesday, July 15, 2020 at 9:00 a.m. Eastern Daylight Time (EDT).

CB2 will issue a press release and file its interim financial statements and interim Quarterly Management Discussion and Analysis (MD&A”) for the quarter ended March 31, 2020 (the Q1 2020 Filings”) after the close of markets on July 14, 2020.

Conference call details:

A replay of the earnings call will be available on the company’s website 24 hours after the call takes place.

Submitting Questions:

Those interested in submitting questions for the earnings call can do so by emailing investors@cb2inisghts.com prior to the start of the call. CB2 Insights will attempt to answer all questions submitted, however some questions may not be answered during the call due to time constraints.

The Company looks forward to providing additional discussion on its Q1 2020 Filings, as well as providing an update on the business and preliminary expectations for Q2 2020. Further, the Company will update shareholders on its future outlook and plans for growth in the coming quarters.

About CB2 Insights

CB2 Insights (CSE:CBII OCT:CBIIF) CB2 Insights is a healthcare services and technology company, working to positively impact patient health outcomes. Our mission to mainstream alternative health treatments into traditional healthcare by recognizing the need for patient treatment diversity, and the impacts of integrating alternative and conventional medicine. The Company works primarily to roster and treat patients who are seeking alternative treatments due to the ineffectiveness of conventional medicine, and the inability to find support through their existing care network, or in some cases, inability to access a primary care network. Medical services offered by the Company are defined as Integrative medicine, where we work to understand the real world evidence for the safety, impact and effectiveness of medical treatments including plant based medicines that often lack sufficient research and therefore adoption by conventional healthcare providers.

To support patient care and positive health outcomes, the Company is also focused on advancing safety and efficacy research surrounding alternative health treatments by monitoring and assessing Real-World Data (RWD) and providing Real-World Evidence (RWE) through our proprietary technology, data analytics, and a full service contract research organization.

The Company’s primary operations are in the United States, with application to its insights, technology and research services deployed in other International markets including Canada, United Kingdom and Colombia.

The Company’s disciplined operating model, allows patients to receive access to care in a time efficient and cost-effective manner. Utilizing virtual telehealth and over 30 physical brick and mortar clinics, the Company currently treats over 100,000 patients across 12 States. Utilizing proprietary technology and data analytic platforms, the Company is able to monitor, study and assess a variety of healthcare treatments and products for the safety, efficacy and effectiveness. The Company believes it is well positioned to be the research and technology partner of choice for multiple stakeholders including Big Pharma, Life Sciences, Regulatory Bodies and Payors within the traditional and integrative medical industry.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2’s filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the Company’s unaudited financial results and projected growth.

Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein.

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.

See the article here:
CB2 Insights to Host Q1 2020 Earnings Call on July 15, 2020 - Stockhouse

Read More...

Nanomedicine Market with Emerging Trends, Global Scope and Demand 2020 to 2026 – The Canton Independent Sentinel

July 10th, 2020 4:45 pm

The Global Nanomedicine Market Report contains essential details of the industry, intended to help the customers identify the optimum approaches to get ahead in the market and make well-informed decisions. An extensive overview of the global sector included in the report examines vital market information to forecast the growth of the market in the forecast duration. The CAGR of the market for the coming years to 2026 has been estimated based on a detailed assessment of the market with authentic and relevant information pertaining to the different segments of the sector. The driving and restraining factors prevailing in the industry have been studied to predict their impact on the growth of the Nanomedicine market in the coming years.

This is the only report that is inclusive of the current effect of the coronavirus on the market and its future trends. The coronavirus has widely impacted the world economy, and its aftereffects are elucidated in detail in the report for the Nanomedicine market.

The sample of the report can be availed by [emailprotected] https://www.reportsanddata.com/sample-enquiry-form/1048

It provides an elaborate breakdown of critical market statistics, market estimation, and profiles of leading players operating in the global Nanomedicine industry.

In market segmentation by manufacturers, the report covers the following companies-

Arrowhead Pharmaceuticals, Inc., Nanospectra Biosciences, Inc., AMAG Pharmaceuticals, Bio-Gate AG, Celgene and Johnson & Johnson

Nanomedicine product types, applications, geographies, and end-user industries are the key market segments that are comprised in this study. The report speculates the prospective growth of the different market segments by studying the current market standing, performance, demand, production, sales, and growth prospects existing in the market.

Get a discount on your copy of the [emailprotected] https://www.reportsanddata.com/discount-enquiry-form/1048

Major highlights of the global Nanomedicine market report:

The report depicts all the analytical details in a well-structured manner, for example, in the statistics, graphs, tables, through which users can more easily grasp detailing. Moreover, it discusses accurate forecasts and gives a detailed research methodology.

The global Nanomedicine market report answers some important questions for you:

Read the full Research Report along with a table of contents, facts and figures, charts, graphs, [emailprotected] https://www.reportsanddata.com/report-detail/nanomedicine-market

To summarize, the global Nanomedicine market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

David is an Experience Business writer who regularly contribute to the blog, He specializes in manufacturing news

Continued here:
Nanomedicine Market with Emerging Trends, Global Scope and Demand 2020 to 2026 - The Canton Independent Sentinel

Read More...

Rheumatoid Arthritis Diagnostic Device Market Expected to Witness an Imperishable Growth over 2025 – Jewish Life News

July 10th, 2020 4:44 pm

Rheumatoid Arthritis Diagnostic Device Market (2018) Report Provides an in-depth summary of Rheumatoid Arthritis Diagnostic Device Market Status as well as Product Specification, Technology Development, and Key Manufacturers. The Report Gives Detail Analysis on Market concern Like Rheumatoid Arthritis Diagnostic Device Market share, CAGR Status, Market demand and up to date Market Trends with key Market segments.

The latest report about the Rheumatoid Arthritis Diagnostic Device market provides a detailed evaluation of the business vertical in question, alongside a brief overview of the industry segments. An exceptionally workable estimation of the present industry scenario has been delivered in the study, and the Rheumatoid Arthritis Diagnostic Device market size with regards to the revenue and volume have also been mentioned. In general, the research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2609409&source=atm

Scope of The Rheumatoid Arthritis Diagnostic Device Market Report:

This research report for Rheumatoid Arthritis Diagnostic Device Market explores different topics such as product scope, product market by end users or application, product market by region, the market size for the specific product Type, sales and revenue by region forecast the Market size for various segments. The Report provides detailed information regarding the Major factors (drivers, restraints, opportunities, and challenges) influencing the growth of the Rheumatoid Arthritis Diagnostic Device market. The Rheumatoid Arthritis Diagnostic Device Market Report analyzes opportunities in the overall Rheumatoid Arthritis Diagnostic Device market for stakeholders by identifying the high-growth segments.

The report firstly introduced the Rheumatoid Arthritis Diagnostic Device basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The major players profiled in this report include:Abbott LaboratoriesDanaher Corp.F. Hoffmann-La Roche Ltd.Siemens Healthineers AGThermo Fisher Scientific Inc.

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-AnalyzersConsumables

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Rheumatoid Arthritis Diagnostic Device for each application, including-HospitalResearch instituteClinic

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2609409&source=atm

A detailed overview of the geographical and competitive sphere of the Rheumatoid Arthritis Diagnostic Device market:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2609409&licType=S&source=atm

Table of Content of The Report

Chapter 1- Rheumatoid Arthritis Diagnostic Device Industry Overview:

1.1 Definition of Rheumatoid Arthritis Diagnostic Device

1.2 Brief Introduction of Major Classifications

1.3 Brief Introduction of Major Applications

1.4 Brief Introduction of Major Regions

Chapter 2- Production Market Analysis:

2.1 Global Production Market Analysis

2.1.1 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis

2.1.2 Major Manufacturers Performance and Market Share

2.2 Regional Production Market Analysis

Chapter 3- Sales Market Analysis:

3.1 Global Sales Market Analysis

3.2 Regional Sales Market Analysis

Chapter 4- Consumption Market Analysis:

4.1 Global Consumption Market Analysis

4.2 Regional Consumption Market Analysis

Chapter 5- Production, Sales and Consumption Market Comparison Analysis

Chapter 6- Major Manufacturers Production and Sales Market Comparison Analysis

Chapter 7- Major Classification Analysis

Chapter 8- Major Application Analysis

Chapter 9- Industry Chain Analysis:

9.1 Up Stream Industries Analysis

9.2 Manufacturing Analysis

Chapter 10- Global and Regional Market Forecast:

10.1 Production Market Forecast

10.2 Sales Market Forecast

10.3 Consumption Market Forecast

Chapter 11- Major Manufacturers Analysis:

11.1.1 Company Introduction

11.1.2 Product Specification and Major Types Analysis

11.1.3 Production Market Performance

11.1.4 Sales Market Performance

11.1.5 Contact Information

11.2.1 Company Introduction

11.2.2 Product Specification and Major Types Analysis

11.2.3 Production Market Performance

11.2.4 Sales Market Performance

11.2.5 Contact Information

Chapter 12- New Project Investment Feasibility Analysis:

12.1 New Project SWOT Analysis

12.2 New Project Investment Feasibility Analysis

Continued

Go here to read the rest:
Rheumatoid Arthritis Diagnostic Device Market Expected to Witness an Imperishable Growth over 2025 - Jewish Life News

Read More...

Drugs for Rheumatoid Arthritis Market Evolution of Key Players That Will Change Industry AbbVie Inc., Boehringer Ingelheim GmbH, Novartis AG – Daily…

July 10th, 2020 4:44 pm

Drugs for Rheumatoid Arthritis Market has witnessed continuous growth within the past few years and is projected to grow even more throughout the forecast period (2020 2027). The analysis presents a whole assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical information, and statistically supported and trade valid market information.

The report, titled Global Drugs for Rheumatoid Arthritis Market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

You Can Request A Demo Version of Report Before Buying (Higher Preference For Corporate Email ID User): https://www.worldwidemarketreports.com/sample/201374

AbbVie Inc., Boehringer Ingelheim GmbH, Novartis AG, Regeneron Pharmaceuticals Inc., Pfizer Inc., Johnson & Johnsons Services Inc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Amgen Inc. of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

1. Industry outlookThis is where youll find the current state of the Drugs for Rheumatoid Arthritis industry overall and where its headed. Relevant industry metrics like size, trends, life cycle, and projected growth included here. This report comes prepared with the data to back up your business idea. On a regional basis, the Global Drugs for Rheumatoid Arthritis market has been segmented into Asia-Pacific, North America, Europe, Latin America, and the Middle East and Africa.

2. Target marketThis target market section of study includes the following:

User persona and characteristics: It includes demographics such as age, income, and location. It lets you know what their interests and buying habits are, as well as explain the best position to meet their needs.

Market size: How big is the potential Drugs for Rheumatoid Arthritis market for your business? It brings to light the consumption in the Drugs for Rheumatoid Arthritis industry by the type and application.

3. Competitive analysisDiscover your competitors. The report lets you know what youre up against, but it also lets you spot the competitions weaknesses. Are there customers that are underserved? What can you offer that similar businesses arent offering? The competitive analysis contains the following components:

Direct competitors: What other companies are offering similar products and services? Which companies are your true competitors?

Competitor strengths and weaknesses: What is your competition good at? Where do they fall behind? Get insights to spot opportunities to excel where others are falling short.

Barriers to entry: What are the potential pitfalls of entering the Drugs for Rheumatoid Arthritis market? Whats the cost of entry? Is it prohibitively high, or easy to enter?

The window of opportunity:Does your entry into the Drugs for Rheumatoid Arthritis industry rely on time-sensitive technology? Do you need to enter early to take advantage of an emerging market?

4. ProjectionsLikewise, We offered thoughtful, not hockey-stick forecasting.

Market share:We have given the consumption behavior of users. When you know how much can your future customers spend, then only youll understand how much of the Drugs for Rheumatoid Arthritis industry you have a chance to grab, and here we came up with real stats and numbers.

Impact Analysis of COVID-19:The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into account the political, economic, social, and technological parameters.

Finally, It is one report that hasnt shied away from taking a critical look at the current status and future outlook for the consumption/sales of these products, by the end users and applications. Not forgetting the market share control and growth rate of the Drugs for Rheumatoid Arthritis Industry, per application. Most noteworthy, this market analysis will help you find market blind spots.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

Go here to read the rest:
Drugs for Rheumatoid Arthritis Market Evolution of Key Players That Will Change Industry AbbVie Inc., Boehringer Ingelheim GmbH, Novartis AG - Daily...

Read More...

Rheumatoid Factor Isotypes, ACPAs Show Strong Associations With Future Cardiovascular Events in RA – Rheumatology Advisor

July 10th, 2020 4:44 pm

Rheumatoid factor (RF) isotypes and anticitrullinated protein antibodies (ACPA) are strongly associated with future cardiovascular (CV) events, including acute coronary syndrome (ACS) and stroke, in patients with rheumatoid arthritis (RA), according to study results published in Arthritis and Rheumatology.

The study cohort included patients from the Swedish Epidemiological Investigation of RA who received a diagnosis of RA between 1996 and 2009 (N=2814). Using these cases, researchers centrally typed baseline serologic data based on the anticyclic citrullinated peptide test (anti-CCP2), 20 ACPA subspecificities, and RF isotypes. Patients were followed over a median 13-year follow-up period through the Swedish national patient register and cause of death register until the first event of ACS, stroke, CV-related mortality, or major adverse CV event (MACE). The association between each serologic marker and CV outcome was examined and adjustments were made for baseline Disease Activity Score in 28 joints (DAS28), smoking, and income level.

During the follow-up period, a total of 375 first ACS, stroke, and CV death events occurred. There was an association between anti-CCP2 positivity and risk for incident ACS (hazard ratio [HR], 1.46; 95% CI, 1.03-2.06; P =.035), stroke (HR, 1.47; 95% CI, 1.03-2.10; P =.034), and MACE (HR, 1.34; 95% CI, 1.06-1.70; P =.014). A similar nonsignificant association was found between anti-CCP2 positivity and CV death (HR, 1.48; 95% CI, 0.94-2.31; P =.087).

Immunoglobulin M (IgM) RF was associated with stroke (HR, 1.42; 95% CI, 1.01-2.01; P =.045) and MACE (HR, 1.40; 95% CI, 1.11-1.76; P =.0045). The researchers also observed a significant association between IgA RF and an increased risk for CV mortality (HR, 1.88; 95% CI, 1.22-2.88; P =.0038). After adjustment for smoking, income, and DAS28, IgA RF remained associated with CV mortality (HR, 1.61; 95% CI, 1.05-2.48). In analyses stratified by smoking status, IgA and IgG RF were associated with CV mortality and IgG and IgM RF were associated with MACE in patients who had never smoked.

Strong associations were found between all-cause mortality and anti-CCP2 positivity, anti-CCP2 level, autoantibody load, the majority of the ACPA subspecificities, and each RF isotype.

A limitation of this study was the lack of adjustment for lipid profile, family history of cardiovascular disease, physical activity, and comorbid conditions.

The researchers suggested that with regard to the risk for CV events, patients with high anti-CPP2 levels or presence of IgA or IgG RF at diagnosis are at higher risk and might benefit from closer monitoring from a cardio preventative perspective.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Westerlind H, Rnnelid J, Hansson M, et al. Anti-citrullinated protein antibody specificities, rheumatoid factor isotypes and incident cardiovascular events in patients with rheumatoid arthritis [published online May 31, 2020]. Arthritis Rheumatol. doi:10.1002/art.41381

Read more here:
Rheumatoid Factor Isotypes, ACPAs Show Strong Associations With Future Cardiovascular Events in RA - Rheumatology Advisor

Read More...

Page 471«..1020..470471472473..480490..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick